<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819792</url>
  </required_header>
  <id_info>
    <org_study_id>PI2011_843_0005</org_study_id>
    <nct_id>NCT01819792</nct_id>
  </id_info>
  <brief_title>Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia</brief_title>
  <acronym>LAMVIRE</acronym>
  <official_title>Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infectious morbidity and mortality is a major complication of AML (Acute Myeloid Leukemia)&#xD;
      induction and consolidation chemotherapies related aplasia. The main aim of this study is to&#xD;
      measure incidence of respiratory viral infections during AML induction and consolidation&#xD;
      chemotherapy related aplasia. Primary end point is a positive polymerase chain&#xD;
      reaction(PCR)associated with clinical signs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial and fungal infection treatment is well defined with guidelines. Few data are&#xD;
      available for viral infections and concern essentially allogeneic stem cell transplantation.&#xD;
      These infections are associated with a high mortality and morbidity rate. Data concerning AML&#xD;
      are essentially retrospective, pediatric and with a little number of patients. Respiratory&#xD;
      viral infections incidence is not known. These infections may be responsible for a higher&#xD;
      mortality rate. Different risk factors are found: age superior to 65 years, lymphopenia,&#xD;
      co-infections. Treatment is subject to a controversy: surveillance or starting an antiviral&#xD;
      therapy. This study aims at understanding viral infections epidemiology during long term&#xD;
      aplasia and optimizing their management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>positivity of the viral PCR in the presence of clinical signs during periods of positivity of the PCR in the presence of clinical signs</measure>
    <time_frame>at day 15</time_frame>
    <description>Positivity of the viral PCR in the presence of clinical signs during periods of Aplasia following chemotherapy induction and consolidation defining viral infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>seasonal viral infection incidence measure</measure>
    <time_frame>18 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk factor of viral infections research</measure>
    <time_frame>18 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral infections related morbidity and mortality estimation</measure>
    <time_frame>18 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bacterial and fungal co-infection estimation</measure>
    <time_frame>18 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>description of antiviral therapeutic used for treating patients</measure>
    <time_frame>18 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>patient with Acute Myeloïd Leukemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multiplex respiratory viral PCR</intervention_name>
    <arm_group_label>patient with Acute Myeloïd Leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old with an AML diagnostic and treated with induction and&#xD;
             consolidation chemotherapy. Patients enrolled in another protocol may be included.&#xD;
&#xD;
          -  Patients with relapsed leukemia who are treated with a salvage intensive therapy stay&#xD;
             in the study&#xD;
&#xD;
          -  Patients who have signed a consent policyholder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients under 18 years old&#xD;
&#xD;
          -  patients treated with another treatment than induction and consolidation chemotherapy&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  patients HIV, HBV or HBC positive&#xD;
&#xD;
          -  patients with a positive PCR at J1&#xD;
&#xD;
          -  patients treated with an antiviral treatment or an immunosuppressive treatment for&#xD;
             another pathology&#xD;
&#xD;
          -  patients under guardianship&#xD;
&#xD;
          -  Primitive immunity Deficit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Pierre MAROLLEAU, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU AMIENS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FABRICE JARDIN, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU ROUEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>OUMEDALY RENAN, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU CAEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BRUNO QUESNEL, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU LILLE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pr Marolleau</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

